ST. LOUIS, Feb. 23, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that Takatsuki General Hospital, a leading acute care institution near Osaka, has completed 250 ablation procedures using the Company’s Niobe® ES remote magnetic navigation system. Takatsuki was the first hospital to order and install the Niobe system after the technology was released in Japan in 2013.
“After being introduced to the Niobe system, I made it a personal goal to be the first physician to bring the next generation of cardiac ablation therapy to the people of Japan,” said Kohei Yamashiro, MD, Heart Rhythm Center Director, Takatsuki General Hospital. “I am pleased and proud that we have completed 250 procedures using the Niobe system, safely and effectively, with even the most complex arrhythmias and those that have failed to respond to other ablation treatments.”
Dr. Yamashiro shared the example of a patient who had suffered from atrial tachycardia for 10 years, which could not be corrected with repeated manual ablation approaches. “With the Niobe system, we were able to completely cure the patient in a single procedure,” he said. “This technology has given us the unique ability to navigate an ablation catheter inside the heart with extreme precision for more exact lesion creation, and with significantly reduced radiation exposure to our patients and staff.”
“Our heart rhythm management services have been greatly enhanced by the important benefits of remote magnetic navigation technology, which has been well received across the region. We are delighted to deliver such an exciting innovation,” continued Dr. Yamashiro.
Takatsuki General Hospital underwent a complete renovation in 2015 to support the latest medical advances, such as the Niobe system, and provide higher quality, more integrated patient services. The first procedures with the Niobe system were performed in July of that year.
About Stereotaxis
Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Over 100 issued patents support the Stereotaxis platform. The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere. For more information, please visit www.stereotaxis.com.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to raise additional capital on a timely basis and on terms that are acceptable, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness, or to obtain additional financing, in either case on acceptable terms, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from healthcare reform in the United States, including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.